David T. Connor

1,3,4-Oxadiazole, 1,3,4-thiadiazole, and 1,2,4-triazole analogs of the fenamates: in vitro inhibition of cyclooxygenase and 5-lipoxygenase activities

Diane H. Boschelli, David T. Connor, Dirk A. Bornemeier et al. · Journal of Medicinal Chemistry · 1993 · 202 citations · Full text

Compound 5B, Medicinal Chemistry, Vitro Inhibition +14

Synthesis and biological evaluation of 5-[[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]methylene]oxazoles, -thiazoles, and -imidazoles: novel dual 5-lipoxygenase and cyclooxygenase inhibitors with antiinflammatory activity

Paul C. Unangst, David T. Connor, Wiaczeslaw A. Cetenko et al. · Journal of Medicinal Chemistry · 1994 · 162 citations · Full text

Synthesis, Structure−Activity Relationships, and in Vivo Evaluations of Substituted Di-<i>tert</i>-butylphenols as a Novel Class of Potent, Selective, and Orally Active Cyclooxygenase-2 Inhibitors. 1. Thiazolone and Oxazolone Series

Yuntao Song, David T. Connor, Robert Doubleday et al. · Journal of Medicinal Chemistry · 1999 · 130 citations · Full text

Pharmaceutical Science, Chemoprevention Strategy, Pharmacotherapy +20

Novel indolecarboxamidotetrazoles as potential antiallergy agents

Paul C. Unangst, David T. Connor, S. Russell Stabler et al. · Journal of Medicinal Chemistry · 1989 · 125 citations

Medicinal Chemistry, Pharmaceutical Chemistry, Anti-inflammatory +13

Synthesis, Structure−Activity Relationships, and in Vivo Evaluations of Substituted Di-<i>tert</i>-butylphenols as a Novel Class of Potent, Selective, and Orally Active Cyclooxygenase-2 Inhibitors. 2. 1,3,4- and 1,2,4-Thiadiazole Series

Yuntao Song, David T. Connor, Anthony D. Sercel et al. · Journal of Medicinal Chemistry · 1999 · 119 citations

Chemoprevention Strategy, Gastrointestinal Pharmacology, Immunology +23